Respiratory virus research during COVID-19
Detection of coronavirus along with other respiratory viruses
Respiratory virus infections are a leading cause of mortality worldwide.
In addition to the threat from single infections, infections with multiple respiratory viruses in the same patient have been reported in many studies.
The severity of viral coinfections on clinical outcome in patients is still unclear. Several investigations concluded that viral coinfections are no more severe than single virus infections.
RSV associated coinfections are more severe than single RSV infections and coinfections with influenza A and B viruses also appear to increase severity, leading to higher rates of admission to intensive care units or death.
Viral coinfection increases severity
Our amplicon-based respiratory viral panel contains over 149 strategically selected targets to cover characteristic regions of a variety of viral segments for highly confident detection and identification.
It is designed for COVID-19, influenza (flu A/B), and RSV (A/B) detection, research, and surveillance. This enables complete genome sequencing of the SARS-CoV-2 virus and concurrent influenza and RSV sub-typing with highly sensitive detection.
The NGS panel not only allows detection and differentiation of the respiratory tract viruses but also enables subtyping and potential strain information for mutation analysis and informed infection control through sequence information.
Compared to most qPCR-based methods, this NGS-based panel covers many more targets for higher sensitivity and is suitable for higher throughput sample pooling on illumine and MGI sequencers related to the respiratory syncytial virus, influenza A subtypes H1N1, H1N2, H3N2, and influenza B.
Accurate identification of viral coinfection
CleanPlex amplicon-based target enrichment method allows highly specific amplification, resulting in high on-target rates and reduced overall sequencing depth per sample. The specificity table below shows the percentage of amplicons with >30X coverage in libraries prepared from each virus control sample using only 50,000 down-sampled reads per sample. The on-target rates for each sample are also shown in the histogram below. The data demonstrate high coverage and on-target rates for detection even at low sequencing depths.
CleanPlex® Respiratory Virus Research Panel Combining Influenza A/B, RSV A/B, and SARS-CoV-2 Testing
CleanPlex® Respiratory Virus Research Panel
The CleanPlex® Respiratory Virus Research Panel combines the original SARS-CoV-2 whole-genome sequencing with expertly designed primers specific to influenza A subtypes H1N1, H1N2, H3N2, influenza B, and respiratory syncytial virus (RSV) A&B.